S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
Conditions: Amorphous, Eosinophilic, and Acellular Deposit; Constipation; Diarrhea; Early Satiety; Gastrointestinal Hemorrhage; Hepatomegaly; Lymphadenopathy; Macroglossia; Nausea; Primary Systemic Amyloidosis; Purpura; Recurrent Primary Amyloidosis; Refractory Primary Amyloidosis Interventions: Biological: Isatuximab; Other: Laboratory Biomarker Analysis Sponsors: Southwest Oncology Group; National Cancer Institute (NCI) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2018 Category: Research Source Type: clinical trials